This post was just published on ZYX Short Change Alert.
MYGN was short sold at $29.75 in the pre-market. As of this writing it is trading at $24.45. One of our rules is to never look a gift horse in the mouth. Consider taking profits and exiting the position right here.
The plan is to short it again on any significant bounce.… Please click here or the title below to read more.
This post was just published on ZYX Short Change Alert.
MYGN’s claim to fame is a test to identify BRCA mutations that increase the risk of breast and ovarian cancers. Previously, DGX announced plans to compete with MYGN.
Today LH announced the nationwide availability of a suite of tests to identify patients with BRCA mutations who are at increased risk for breast, ovarian and other cancers. The BRCAssure tests will be available through LH as well as Integrated Genetics and Integrated Oncology, members of LH’s Specialty Testing Group. LH’s BRCAssure BRCA1/2 Analysis will include full gene sequencing of BRCA1/2 genes and duplication/deletion testing, with a variant of unknown significance rate of less than 5%.… Please click here or the title below to read more.